CycLex® Cdc25A Protein Phosphatase Fluorometric Assay Kit

  • Target Cdc25A
  • Code # CY-1352
  • Size 100 Assays
  • Price


Activation of cyclin-dependent kinases in higher eukaryotic cells can be achieved through dephosphorylation of two conserved residues, Thr14 and Tyr15 (1) by members of the Cdc25 phosphatase family, Cdc25A, Cdc25B and Cdc25C. The Cdc25 dual-specificity phosphatases control progression through the eukaryotic cell division cycle by activating cyclin-dependent kinases. Cdc25A plays an important role at the G1/S-phase transition. Cdc25A degradation during mitotic exit and in early G1 is mediated by the anaphase-promoting complex or cyclosome (APC/C)(Cdh1) ligase, and that a KEN-box motif in the N-terminus of the protein is required for its targeted degradation (2, 3). Cdc25B undergoes activation during S-phase and plays a role in activating the mitotic kinase Cdk1/cyclin B in the cytoplasm (4-6). Active Cdk1/cyclin B then phosphorylates and activates Cdc25C leading to a positive feedback mechanism and to entry into mitosis. In addition to their essential function in the normal cell cycle, cdc25 phosphatases are involved in the checkpoint-induced control of cell cycle progression (7-9). Finally, Cdc25A and B phosphatases have been shown to possess an important oncogenic potential and to be overexpressed in a variety of cancers and cancer cell lines (4, 10).
  • Components:
    • 10x Assay Buffer
    • 10x 3-o-methyl fluorescein phosphate (OMFP)
    • Recombinant Human Cdc25A
    • 100x Cdc25 Inhibitor
    • Stop Solution
  • Description:

    The CycLex Cdc25A Combo Fluorometric Assay Kit is a fluorometric and non-radioactive assay designed to measure the activity of Cdc25A protein phosphatase. It can be used for 100 assays.

  • Product Type:
  • Short Description:

    CycLex Cdc25A Protein Phosphatase Fluorometric Assay Kit.

  • Size:
    100 Assays
  • Storage Temperature:
    -20°C. Please refer to datasheet for additional information
  • Target:
  1. Ajeawung NF et al. Preclinical evaluation of dipotassium bisperoxo (picolinato) oxovanadate V for the treatment of pediatric low-grade gliomas. Future Oncol. 9, 1215-29 (2013)
  1. Morgan, D. O. (1997) Annu. Rev. Cell Dev. Biol. 13, 261-291
  2. Jinno, S., Suto, K., Nagata, A., Igarashi, M., Kanaoka, Y., Nojima, H., and Okayama, H. (1994) EMBO J. 13, 1549-1556 3. Hoffmann, I., Draetta, G., and Karsenti, E. (1994) EMBO J. 13, 4302-4310
  3. Nagata, A., Igarashi, M., Jinno, S., Suto, K., and Okayama, H. (1991) New Biol. 3, 959-968
  4. Karlsson, C., Katich, S., Hagting, A., Hoffmann, I., and Pines, J. (1999) J. Cell Biol. 146, 573-583
  5. Hoffmann, I., Clarke, P. R., Marcote, M. J., Karsenti, E., and Draetta, G. (1993) EMBO J. 12, 53-63
  6. Furnari, B., Rhind, N., and Russell, P. (1997) Science 277, 1495-1497
  7. Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., and Elledge, S. J. (1997) Science 277, 1497-1501
  8. Peng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., and Piwnica-Worms, H. (1997) Science 277, 1501-1505
  9. Galaktionov, K., Lee, A. K., Eckstein, J., Draetta, G., Meckler, J., Loda, M., and Beach, D. (1995)
  10. Science 269, 1575-1577